

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplement Table 1: Study characteristics of included studies

Study Identifier	Study description	Duration, weeks	Subject population
NCT00528372[9]	Dapagliflozin monotherapy	24 + 78	Drug-naïve patients with HbA1c $\geq 7.0\%$ and $\leq 10.0\%$
NCT00528879 [2]	Dapagliflozin added to metformin	24 + 78	Patients on metformin ≥ 1500 mg/day with HbA1c $\geq 7.0\%$ and $\leq 10.0\%$
NCT00680745[12]	Dapagliflozin added to SU-derivatives	24 + 24	Patients on SU with HbA1c $\geq 7.0\%$ and $\leq 10.0\%$
NCT00663260[7]	Dapagliflozin in patients with moderate renal impairment	24 + 80	Patients with moderate renal impairment (GFR >30 to <60 mL/min/1.73m ² on a stable antidiabetic regimen with HbA1c $\geq 7\%$ and $\leq 11\%$)
NCT00683878[13]	Dapagliflozin added to thiazolidinediones	24 + 24	Patients on pioglitazone with HbA1c $\geq 7.0\%$ and $\leq 10.5\%$
NCT00673231[11]	Dapagliflozin added to insulin	24 + 80	Patients on insulin ≥ 30 IU/day \pm maximum 2 OAD with HbA1c $\geq 7.5\%$ and $\leq 10.5\%$
NCT00859898[14]	Initial combination of dapagliflozin and metformin	24	Treatment-naïve patients with HbA1c $\geq 7.5\%$ and $\leq 12.0\%$
NCT00984867[16]	Dapagliflozin added to DPP-4 inhibitor	24 + 24	Drug-naïve patients or patients on sitagliptin/vildagliptin \pm metformin with HbA1c $\geq 7.0\%$ and $\leq 10.0\%$)
NCT00855166 [10]	Dapagliflozin added to metformin	24 + 78	Patients on metformin ≥ 1500 mg/day with HbA1c $\geq 6.5\%$ and $\leq 8.5\%$
NCT01031680[17]	Dapagliflozin in patients at high CV risk	24 + 80	Patients on usual care for diabetes with CVD and hypertension and HbA1c $\geq 7.0\%$ and $\leq 10.0\%$
NCT01042977[15]	Dapagliflozin in patients at high CV risk	24 + 80	Patients on usual care for diabetes with CVD and HbA1c $\geq 7.0\%$ and $\leq 10.0\%$

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplementary Figure 1: Effect of dapagliflozin on (A) diastolic blood pressure and (B) pulse pressure and (C) uric acid is independent of baseline eGFR.

